Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.

J Hematol Oncol · 2017 · PMC5244709 · PMID 28103904

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients who received fruquintinib showed a trend of prolonged median OS (7.72 months) compared with those who received placebo (5.52 months); however, the difference was not significant (stratified HR 0.71; 95% CI 0.38–1.34; Fig. 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.